Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 49, 6242-6246, November 15, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanae, F.
Right arrow Articles by Koshiura, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanae, F.
Right arrow Articles by Koshiura, R.

Altered Adrenergic Response and Specificity of the Receptors in Rat Ascites Hepatoma AH130

Fujiko Sanae, Ken-ichi Miyamoto1 and Ryozo Koshiura

Third Division of the Research Laboratory for Development of Medicine, School of Pharmacy, Hokuriku University, Ho-3 Kanagawa-machi, Kanazawa 920-11, Japan

Adenylate cyclase activation through adrenergic receptors in rat ascites hepatoma (AH) 130 cells in response to adrenergic drugs was studied, and receptor binding and displacement were compared with those of normal rat hepatocytes. Epinephrine (Epi) and norepinephrine (NE) activated AH130 adenylate cyclase about half as much as isoproterenol (IPN) but equaled IPN after treatment with the {alpha}-antagonist phentolamine or islet-activating protein (IAP). The three catecholamines in hepatocytes were similar regardless of phentolamine or IAP. These catecholamines activated adenylate cyclase in order of IPN > NE > Epi in AH130 cells but IPN > Epi > NE in hepatocytes. We then used the {alpha}1-selective ligand [3H]prazosin, the {alpha}2-selective ligand [3H]clonidine, and the ß-ligand [125I]iodocyanopindolol ([125I]ICYP), and found that AH130 cells had few prazosin-binding sites, about eight times as many clonidine-binding sites with high affinity, and many more ICYP-binding sites than in hepatocytes. The dissociation constant (Ki) of the ß1-selective drug metoprolol by Hofstee plots for AH130 cells was lower than that for hepatocytes. The inhibition of specific ICYP binding by the ß2-selective agonist salbutamol for AH130 cells gave only one Ki value which was much higher than both high and low Ki values of the drug for hepatocytes. These findings indicate that the {alpha}- and ß-adrenergic receptors in hepatocytes are predominantly {alpha}1- type and ß2-type, but that those in AH130 cells are predominantly {alpha}2-type and ß1-type, and the low adrenergic response of AH130 cells is due to the dominant appearance of {alpha}2-adrenergic receptors, linked with the inhibitory guanine-nucleotide binding regulatory protein, instead of {alpha}1-adrenergic receptors, and ß1-adrenergic receptors with low affinity for the hormone.

1 To whom requests for reprints should be addressed.

Received 4/20/89. Revised 7/13/89. Accepted 8/17/89.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1989 by the American Association for Cancer Research.